93 related articles for article (PubMed ID: 10319748)
21. Technetium-99m-MIBI in primary and recurrent head and neck tumors: contribution of bone SPECT image fusion.
Leitha T; Glaser C; Pruckmayer M; Rasse M; Millesi W; Lang S; Nasel C; Backfrieder W; Kainberger F
J Nucl Med; 1998 Jul; 39(7):1166-71. PubMed ID: 9669388
[TBL] [Abstract][Full Text] [Related]
22. Immunoscintigraphy of venous thrombi: clinical effectiveness of a new antifibrin D-dimer monoclonal antibody.
Ciavolella M; Tavolaro R; Di Loreto M; La Torre F; Nicolai A; Schillaci O; Ierardi M; Scopinaro F
Angiology; 1999 Feb; 50(2):103-9. PubMed ID: 10063940
[TBL] [Abstract][Full Text] [Related]
23. [Direct and indirect labeling with 99mTc of an antireceptor monoclonal antibody of EGF].
Calderón Sánchez O; Zayas Crespo F; Leyva Montaña R; Beckford Vera D; Gómez JA
Rev Esp Med Nucl; 2005; 24(1):38-44. PubMed ID: 15701345
[TBL] [Abstract][Full Text] [Related]
24. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer.
de Bree R; Roos JC; Quak JJ; den Hollander W; Snow GB; van Dongen GA
Clin Cancer Res; 1995 Jun; 1(6):591-8. PubMed ID: 9816020
[TBL] [Abstract][Full Text] [Related]
25. Anti-melanoma monoclonal antibody 225.28S immunoscintigraphy in metastatic melanoma.
Böni R; Huch Böni RA; Steinert H; Dummer R; Burg G; von Schulthess GK
Dermatology; 1995; 191(2):119-23. PubMed ID: 8520057
[TBL] [Abstract][Full Text] [Related]
26. Technetium-99m-sestamibi scintimammography for the detection of breast carcinoma: comparison between planar and SPECT imaging.
Tiling R; Tatsch K; Sommer H; Meyer G; Pechmann M; Gebauer K; Münzing W; Linke R; Khalkhali I; Hahn K
J Nucl Med; 1998 May; 39(5):849-56. PubMed ID: 9591588
[TBL] [Abstract][Full Text] [Related]
27. Immunoscintigraphy with a technetium-99m labelled anti-epithelial growth factor receptor antibody in patients with non-small cell lung cancer.
Schillaci O; Danieli R; Picardi V; Bagni O; Di Loreto M; Scopinaro F
Anticancer Res; 2001; 21(5):3571-4. PubMed ID: 11848525
[TBL] [Abstract][Full Text] [Related]
28. Tumor targeting using anti-epidermal growth factor receptor (ior egf/r3) immunoconjugate with a tetraaza macrocyclic agent (DO3A-EA).
Mishra G; Panwar P; Mishra AK
Mol Imaging; 2012; 11(5):408-16. PubMed ID: 22954185
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT.
Gainkam LO; Huang L; Caveliers V; Keyaerts M; Hernot S; Vaneycken I; Vanhove C; Revets H; De Baetselier P; Lahoutte T
J Nucl Med; 2008 May; 49(5):788-95. PubMed ID: 18413403
[TBL] [Abstract][Full Text] [Related]
30. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.
Crombet T; Osorio M; Cruz T; Roca C; del Castillo R; Mon R; Iznaga-Escobar N; Figueredo R; Koropatnick J; Renginfo E; Fernández E; Alvárez D; Torres O; Ramos M; Leonard I; Pérez R; Lage A
J Clin Oncol; 2004 May; 22(9):1646-54. PubMed ID: 15117987
[TBL] [Abstract][Full Text] [Related]
31. A novel multivalent (99m)Tc-labeled EG2-C4bpα antibody for targeting the epidermal growth factor receptor in tumor xenografts.
Li C; Zhang Y; Wang L; Feng H; Xia X; Ma J; Yuan H; Gao B; Lan X
Nucl Med Biol; 2015 Jun; 42(6):547-54. PubMed ID: 25779037
[TBL] [Abstract][Full Text] [Related]
32. In vivo and in vitro characterizations of three 99mTc-labeled monoclonal antibody G250 preparations.
Steffens MG; Oosterwijk E; Kranenborg MH; Manders JM; Debruyne FM; Corstens FH; Boerman OC
J Nucl Med; 1999 May; 40(5):829-36. PubMed ID: 10319758
[TBL] [Abstract][Full Text] [Related]
33. Immunoscintigraphy With 99mTc-Nimotuzumab for Planning Immunotherapy in Patients With Bone Metastases Due to Prostate Cancer.
Quián YP; Crombet T; Batista JF; Prats A; Perera A
Clin Nucl Med; 2016 Mar; 41(3):244-6. PubMed ID: 26447381
[TBL] [Abstract][Full Text] [Related]
34. Comparison of parathyroid imaging with technetium-99m-pertechnetate/sestamibi subtraction, double-phase technetium-99m-sestamibi and technetium-99m-sestamibi SPECT.
Chen CC; Holder LE; Scovill WA; Tehan AM; Gann DS
J Nucl Med; 1997 Jun; 38(6):834-9. PubMed ID: 9189125
[TBL] [Abstract][Full Text] [Related]
35. Scintigraphic determination of equivocal appendicitis.
Rypins EB; Kipper SL
Am Surg; 2000 Sep; 66(9):891-5. PubMed ID: 10993624
[TBL] [Abstract][Full Text] [Related]
36. Immunoscintigraphy and radioimmunotherapy in Cuba: experiences with labeled monoclonal antibodies for cancer diagnosis and treatment (1993-2013).
Peña Y; Perera A; Batista JF
MEDICC Rev; 2014; 16(3-4):55-60. PubMed ID: 25208121
[TBL] [Abstract][Full Text] [Related]
37. [Radioimmunoscintigraphy of colorectal cancer using the anti-CEA monoclonal antibody BW 431/26. Final results].
Oliva J; Pimentel G; Peralta R; Borrón M; Ortiz R; Gutiérrez J; Guerra J; Quesada W; Dopico R; Casanova F; Baum RP
Rev Esp Med Nucl; 1999; 18(1):5-15. PubMed ID: 10074212
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical evaluation of H-R3 a novel humanized monoclonal antibody that neutralizes the EGF-receptor.
Cedeño-Arias M; Rengifo CE; Batista YR; Calzado ER; Rodríguez T
Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):213-9. PubMed ID: 17525637
[TBL] [Abstract][Full Text] [Related]
39. Interspecies scaling of the monoclonal anti-EGF receptor ior EGF/r3 antibody disposition using allometric paradigm: is it really suitable?
Ducongé J; Fernández-Sánchez E; Alvarez D
Biopharm Drug Dispos; 2004 May; 25(4):177-86. PubMed ID: 15108220
[TBL] [Abstract][Full Text] [Related]
40. Improvement of radiation treatment planning in squamous-cell head and neck cancer by immuno-SPECT.
Adamietz IA; Baum RP; Schemman F; Niesen A; Knecht R; Saran F; Tieku S; Boniface GR; Hör G; Böttcher HD
J Nucl Med; 1996 Dec; 37(12):1942-6. PubMed ID: 8970510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
